The prize recognizes foundational discoveries about regulatory T cells and the FOXP3 gene that redefined immune tolerance and opened avenues to treat autoimmune disease, enable transplantation, and advance immuno-oncology. ISB celebrates Dr. Brunkow’s leadership and collaborative science.
The pioneering work of Mary Brunkow and Fred Ramsdell began with a mysterious mutant mouse known as “scurfy,” leading them to identify the FOXP3 gene and unlock how regulatory T cells prevent autoimmune disease — discoveries that now point to new treatments in cancer and autoimmunity.
Researchers at ISB have developed personalized models to predict C. diff colonization risk and test targeted probiotics. This approach could prevent infection before it starts and paves the way for precision microbiome therapies tailored to individual gut ecosystems.
ISB scientists have developed a simple, low-cost method to measure the total amount of bacteria in the gut using existing sequencing data. This breakthrough could speed up microbiome research and unlock new insights into health and disease.
Researchers from the NIH-funded RECOVER study shared new insights on the risks of Long COVID, autoimmune links, and upcoming clinical trials during ISB’s July Town Hall.
The Biomedical Data Translator is now publicly available, offering a powerful open-source platform that integrates diverse biomedical datasets. Designed to accelerate discovery and patient care, Translator helps users explore complex data and uncover actionable insights with ease.
In a Research Roundtable presentation and Q&A, ISB President Dr. Jim Heath shared how his team is using generative AI to unlock new understanding of human immunity, and how these discoveries could help predict disease severity, improve cancer therapies, and more.
Just-published research out of ISB shows the microbial teamwork behind denitrification can collapse in polluted environments, threatening ecosystem balance and resilience.